Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-2.08% $2.82
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 94.84 mill |
EPS: | -6.15 |
P/E: | -0.460 |
Earnings Date: | May 06, 2024 |
SharesOutstanding: | 33.63 mill |
Avg Daily Volume: | 1.584 mill |
RATING 2024-03-28 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Buy | |
Return On Asset: | Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | |||||
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.460 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.08x |
Company: PE -0.460 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-1.057 (-137.48%) $-3.88 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 2.51 - 3.13 ( +/- 10.89%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-14 | Yocca Frank | Buy | 521 | Common Stock |
2023-12-14 | Yocca Frank | Sell | 521 | Restricted Stock Units |
2023-12-14 | Mehta Vimal | Buy | 2 609 | Common Stock |
2023-12-14 | Mehta Vimal | Sell | 2 609 | Restricted Stock Units |
2023-12-14 | Rodriguez Javier | Buy | 521 | Common Stock |
INSIDER POWER |
---|
-11.07 |
Last 81 transactions |
Buy: 351 248 | Sell: 440 033 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.82 (-2.08% ) |
Volume | 0.336 mill |
Avg. Vol. | 1.584 mill |
% of Avg. Vol | 21.21 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $3.74 | N/A | Active |
---|
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.